141 related articles for article (PubMed ID: 17082510)
21. Survivin expression as a prognostic factor in patients with epithelial ovarian cancer or primary peritoneal cancer treated with neoadjuvant chemotherapy.
Gąsowska-Bodnar A; Bodnar L; Dąbek A; Cichowicz M; Jerzak M; Cierniak S; Kozłowski W; Baranowski W
Int J Gynecol Cancer; 2014 May; 24(4):687-96. PubMed ID: 24662134
[TBL] [Abstract][Full Text] [Related]
22. Paclitaxel/carboplatin versus cyclophosphamide/carboplatin in peritoneal carcinomatosis of the ovary.
Balat O
Eur J Gynaecol Oncol; 2004; 25(2):195-6. PubMed ID: 15032280
[TBL] [Abstract][Full Text] [Related]
23. Hypomagnesemia and Survival in Patients with Ovarian Cancer Who Received Chemotherapy with Carboplatin.
Liu W; Qdaisat A; Soliman PT; Ramondetta L; Lopez G; Narayanan S; Zhou S; Cohen L; Bruera E; Yeung SJ
Oncologist; 2019 Jun; 24(6):e312-e317. PubMed ID: 30940743
[TBL] [Abstract][Full Text] [Related]
24. Performance status rather than age is the key prognostic factor in second-line treatment of elderly patients with epithelial ovarian carcinoma.
Gronlund B; Høgdall C; Hansen HH; Engelholm SA
Cancer; 2002 Apr; 94(7):1961-7. PubMed ID: 11932898
[TBL] [Abstract][Full Text] [Related]
25. Changes in Ki-67 labeling indices during neoadjuvant chemotherapy for advanced ovarian cancer are associated with survival.
Pölcher M; Friedrichs N; Rudlowski C; Fimmers R; Keyver-Paik MD; Kübler K; Sauerwald A; Büttner R; Kuhn W; Braun M
Int J Gynecol Cancer; 2010 May; 20(4):555-60. PubMed ID: 20442588
[TBL] [Abstract][Full Text] [Related]
26. Weight change during chemotherapy as a potential prognostic factor for stage III epithelial ovarian carcinoma: a Gynecologic Oncology Group study.
Hess LM; Barakat R; Tian C; Ozols RF; Alberts DS
Gynecol Oncol; 2007 Nov; 107(2):260-5. PubMed ID: 17675142
[TBL] [Abstract][Full Text] [Related]
27. Decreased dose density of standard chemotherapy does not compromise survival for ovarian cancer patients.
Molckovsky A; Vijay SM; Hopman WM; Bryson P; Jeffrey JF; Biagi JJ
Int J Gynecol Cancer; 2008; 18(1):8-13. PubMed ID: 17511802
[TBL] [Abstract][Full Text] [Related]
28. The importance of chemotherapy and radiation in uterine papillary serous carcinoma.
Viswanathan AN; Macklin EA; Berkowitz R; Matulonis U
Gynecol Oncol; 2011 Dec; 123(3):542-7. PubMed ID: 21963091
[TBL] [Abstract][Full Text] [Related]
29. Association between in vitro platinum resistance in the EDR assay and clinical outcomes for ovarian cancer patients.
Holloway RW; Mehta RS; Finkler NJ; Li KT; McLaren CE; Parker RJ; Fruehauf JP
Gynecol Oncol; 2002 Oct; 87(1):8-16. PubMed ID: 12468336
[TBL] [Abstract][Full Text] [Related]
30. Bevacizumab combined with platinum-taxane chemotherapy as first-line treatment for advanced ovarian cancer: a prospective observational study of safety and efficacy in Japanese patients (JGOG3022 trial).
Komiyama S; Kato K; Inokuchi Y; Takano H; Matsumoto T; Hongo A; Asai-Sato M; Arakawa A; Kamiura S; Tabata T; Takeshima N; Sugiyama T
Int J Clin Oncol; 2019 Jan; 24(1):103-114. PubMed ID: 30030657
[TBL] [Abstract][Full Text] [Related]
31. Is there a high-risk subgroup of stage I epithelial ovarian cancer that is most likely to benefit from 6 versus 3 cycles of adjuvant chemotherapy?
Bakkum-Gamez JN; Richardson DL; Seamon LG; Aletti GD; Powless CA; Keeney GL; O'Malley DM; Cliby WA
Int J Gynecol Cancer; 2010 Oct; 20(7):1125-31. PubMed ID: 21495213
[TBL] [Abstract][Full Text] [Related]
32. Progress in survival outcomes in patients with advanced ovarian cancer treated by neo-adjuvant platinum/taxane-based chemotherapy and late interval debulking surgery.
Stoeckle E; Bourdarias L; Guyon F; Croce S; Brouste V; Thomas L; Floquet A
Ann Surg Oncol; 2014 Feb; 21(2):629-36. PubMed ID: 24052318
[TBL] [Abstract][Full Text] [Related]
33. The predictors of response to neoadjuvant chemotherapy in advanced epithelial ovarian cancer.
Yildirim Y; Ertas IE; Dogan A; Gultekin OE; Gultekin E
J Surg Oncol; 2012 Feb; 105(2):200-5. PubMed ID: 21815151
[TBL] [Abstract][Full Text] [Related]
34. Carboplatin plus paclitaxel once a week versus every 3 weeks in patients with advanced ovarian cancer (MITO-7): a randomised, multicentre, open-label, phase 3 trial.
Pignata S; Scambia G; Katsaros D; Gallo C; Pujade-Lauraine E; De Placido S; Bologna A; Weber B; Raspagliesi F; Panici PB; Cormio G; Sorio R; Cavazzini MG; Ferrandina G; Breda E; Murgia V; Sacco C; Cinieri S; Salutari V; Ricci C; Pisano C; Greggi S; Lauria R; Lorusso D; Marchetti C; Selvaggi L; Signoriello S; Piccirillo MC; Di Maio M; Perrone F; ; ; ; ;
Lancet Oncol; 2014 Apr; 15(4):396-405. PubMed ID: 24582486
[TBL] [Abstract][Full Text] [Related]
35. Primary chemotherapy in stage IV ovarian cancer. A prospective phase II study.
Recchia F; De Filippis S; Rosselli M; Saggio G; Carta G; Rea S
Eur J Gynaecol Oncol; 2001; 22(4):287-91. PubMed ID: 11695811
[TBL] [Abstract][Full Text] [Related]
36. Phase I and pharmacologic study of the combination paclitaxel and carboplatin as first-line chemotherapy in stage III and IV ovarian cancer.
Huizing MT; van Warmerdam LJ; Rosing H; Schaefers MC; Lai A; Helmerhorst TJ; Veenhof CH; Birkhofer MJ; Rodenhuis S; Beijnen JH; ten Bokkel Huinink WW
J Clin Oncol; 1997 May; 15(5):1953-64. PubMed ID: 9164207
[TBL] [Abstract][Full Text] [Related]
37. Increased incidence of severe gastrointestinal events with first-line paclitaxel, carboplatin, and vorinostat chemotherapy for advanced-stage epithelial ovarian, primary peritoneal, and fallopian tube cancer.
Mendivil AA; Micha JP; Brown JV; Rettenmaier MA; Abaid LN; Lopez KL; Goldstein BH
Int J Gynecol Cancer; 2013 Mar; 23(3):533-9. PubMed ID: 23385285
[TBL] [Abstract][Full Text] [Related]
38. Paclitaxel with carboplatin versus paclitaxel with carboplatin alternating with cisplatin as first-line chemotherapy in advanced epithelial ovarian cancer: preliminary results of a Hellenic Cooperative Oncology Group study.
Skarlos DV; Aravantinos G; Kosmidis P; Athanassiadis A; Stathopoulos GP; Pavlidis N; Bafaloukos D; Karphathios S; Papakostas P; Bamia C; Fountzilas G
Semin Oncol; 1997 Oct; 24(5 Suppl 15):S15-57-S15-61. PubMed ID: 9346224
[TBL] [Abstract][Full Text] [Related]
39. Standard first-line chemotherapy with or without nintedanib for advanced ovarian cancer (AGO-OVAR 12): a randomised, double-blind, placebo-controlled phase 3 trial.
du Bois A; Kristensen G; Ray-Coquard I; Reuss A; Pignata S; Colombo N; Denison U; Vergote I; Del Campo JM; Ottevanger P; Heubner M; Minarik T; Sevin E; de Gregorio N; Bidziński M; Pfisterer J; Malander S; Hilpert F; Mirza MR; Scambia G; Meier W; Nicoletto MO; Bjørge L; Lortholary A; Sailer MO; Merger M; Harter P;
Lancet Oncol; 2016 Jan; 17(1):78-89. PubMed ID: 26590673
[TBL] [Abstract][Full Text] [Related]
40. [A multicenter randomized clinical trial of weekly paclitaxel and carboplatin vs three weeks paclitaxel and carboplatin as first line chemotherapy in epithelial ovarian cancer].
Shen K; Li MD; Feng YJ; Ma D; Li ZT; Xie X; Kong BH; Cui H; Song L; Peng ZL; Li L; Wu M; Chen YL; Lui JH; Wu LY; Lang JH;
Zhonghua Yi Xue Za Zhi; 2005 Aug; 85(30):2099-103. PubMed ID: 16313817
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
